Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 5,517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Statin Adverse Reaction
Interventions: Low-dose colchicine at 0.5mg daily, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COVID-19
Interventions: Rivaroxaban, Placebo; Drug
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more

Conditions: Obesity, Overweight, Type 2 Diabetes
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more

Conditions: Autism Spectrum Disorder
Interventions: Transdermal Neuromodulation Stimulation; Device
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 10 Years to 25 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes Mellitus, Type 1
Interventions: TTP399, Placebo Oral Tablet; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Beverly Hills, California • Escondido, California • Aurora, Colorado + 12 more

Conditions: Pulmonary Sarcoidosis
Interventions: OATD-01, Placebo; Drug
Lead sponsor: Molecure S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Weight Management
Interventions: GS-4571, Placebo, Omeprazole; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: HIV
Interventions: PC-1005, HEC gel; Drug
Lead sponsor: Population Council; Other
Eligibility: 19 Years to 49 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Momelotinib, Placebo to match momelotinib, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Goshen, Indiana • Boston, Massachusetts + 1 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Conditions: Plaque Psoriasis
Interventions: AGN-242428, Placebo; Drug
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Rivoglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 70
States / cities: Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more

Conditions: Dental Caries
Interventions: Fluoride free toothpaste, Fluoride toothpaste, Fluoride mouthwash; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Eosinophilic Esophagitis
Interventions: Etrasimod, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 221
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 85 more

Conditions: Benign Prostatic Hyperplasia
Interventions: tadalafil, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Greenwood, Indiana

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584, Matching Placebo, Latanoprost 0.005%; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 8
States / cities: Chandler, Arizona • Artesia, California • Inglewood, California + 5 more

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 8
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more

Conditions: Obstructive Sleep Apnea
Interventions: IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide; Drug
Lead sponsor: Incannex Healthcare Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Chula Vista, California • Long Beach, California • Upland, California + 16 more

Conditions: Alzheimer's Disease (AD)
Interventions: ABBV-552, Placebo for ABBV-552; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 37
States / cities: Irvine, California • Long Beach, California • Los Alamitos, California + 31 more

Conditions: Smoking Cessation
Interventions: Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8,144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more

Conditions: Ascites, Liver Cirrhosis
Interventions: Satavaptan, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Malvern, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Protein, Carbohydrate (Placebo), Resistance Exercise Program; Dietary Supplement · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 95 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more

Conditions: Cardiac Failure Aggravated
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 1 more

Search by objective public record fields.

Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

High-Frequency Transdermal Neuromodulation to Decrease Anxiety and Improve Sleep in ASD

Evaluation of TTP399 in Patients With Type 1 Diabetes

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

AGN-242428 in the Treatment of Plaque Psoriasis

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Evaluation of Oral Hygiene Products in an In Situ Caries Model

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure